
Source: businesswire | Published on: Tuesday, 11 March 2025
DUBLIN--(BUSINESS WIRE)--The "Enterprise Tech Ecosystem Series: GSK plc 2024" company profile has been added to ResearchAndMarkets.com's offering.
The report provides insights into company's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives.
GSK plc (GSK) is a healthcare company that focuses on developing, manufacturing and commercializing general medicines, specialty medicines and vaccines. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, and urogenital, anti-bacterial, dermatology and rare diseases.
The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastrointestinal diseases. GSK's vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide.
The report provides information and insights into GSK's tech activities, including:
Reasons to Buy
Key Topics Covered:
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this company profile visit https://www.researchandmarkets.com/r/a2ycq8
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.